XJPX4564
Market cap39mUSD
Jan 21, Last price
23.00JPY
1D
0.00%
1Q
-25.81%
Jan 2017
-91.45%
Name
OncoTherapy Science Inc
Chart & Performance
Profile
OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | 2015‑03 | |
Income | ||||||||||
Revenues | 610,118 -46.24% | 1,134,903 -1.63% | 1,153,663 246.99% | |||||||
Cost of revenue | 1,730,917 | 2,241,318 | 3,206,300 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (1,120,799) | (1,106,415) | (2,052,637) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 2,425 | 2,223 | 1,234 | |||||||
Tax Rate | ||||||||||
NOPAT | (1,123,224) | (1,108,638) | (2,053,871) | |||||||
Net income | (1,288,138) 15.15% | (1,118,644) -56.50% | (2,571,541) 64.67% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 682,552 | 1,466,717 | ||||||||
BB yield | -16.04% | -11.34% | ||||||||
Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | 106,849 | |||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 47,165 | 47,046 | 99,706 | |||||||
Net debt | (469,807) | (1,206,635) | (1,920,906) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (1,227,990) | (794,901) | (2,073,224) | |||||||
CAPEX | (2,627) | (5,393) | (456,949) | |||||||
Cash from investing activities | (33,354) | (20,319) | (467,928) | |||||||
Cash from financing activities | 671,365 | 95,950 | 1,478,967 | |||||||
FCF | (1,123,224) | (949,899) | (2,017,582) | |||||||
Balance | ||||||||||
Cash | 527,656 | 1,117,635 | 1,836,906 | |||||||
Long term investments | 49,000 | 89,000 | 84,000 | |||||||
Excess cash | 546,150 | 1,149,890 | 1,863,223 | |||||||
Stockholders' equity | (25,969,962) | (23,938,449) | (22,813,385) | |||||||
Invested Capital | 26,477,644 | 24,771,283 | 24,756,790 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 212,783 | 192,644 | 187,466 | |||||||
Price | 20.00 -57.45% | 47.00 -31.88% | 69.00 -43.90% | |||||||
Market cap | 4,255,669 -53.00% | 9,054,254 -30.00% | 12,935,172 -40.36% | |||||||
EV | 3,785,862 | 7,847,619 | 11,014,266 | |||||||
EBITDA | (1,120,799) | (1,106,415) | (2,036,097) | |||||||
EV/EBITDA | ||||||||||
Interest | 218 | 5,372 | ||||||||
Interest/NOPBT |